Evidence is continuing to accumulate that the FMS-like tyrosine kinase 3 (FLT3) receptor plays an important role in acute leukemias. Acute myeloid leukemia patients often express constitutive active mutant forms of the receptor in their leukemic cells. A t(12;13)(p13;q12) translocation between Tel and the FLT3 receptor was recently described in a patient with myeloproliferative disease (MPD). Here a Tel-FLT3 construct mimicking this fusion protein was used to generate transgenic mice. The fusion protein was previously found to constitutively activate FLT3 signaling and transform Ba/F3 cells. Expression of the fusion protein in the transgenic mice was found in all tissues assayed including spleen, bone marrow (BM), thymus and liver. These mice developed splenomegaly and had a high incidence of MPD with extramedullary hematopoiesis in the liver and lymph nodes. Spleens also had increased dendritic and natural killer cell populations. In vitro analysis of the hematopoietic progenitor cells derived from Tel-FLT3 transgenic mice showed a significant increase in the number of CFU-GM in the BM, and CFU-GM, BFU-E and CFU-GEMM in the spleen. BM also showed significant increases of in vivo CFU-S colonies. Thus, transgenic mice expressing constitutively activated Tel-FLT3 develop MPD with a long latency and also result in the expansion of the hematopoietic stem/progenitor cells.
Introduction
Accumulating data indicate an important role for the type III human hematopoietic receptor tyrosine kinase FLT3 (FMS-like tyrosine kinase 3, also known as FLK-2, STK-1 or CD135) in a substantial fraction of acute leukemias. 1, 2 Normally, the FLT3 receptor is activated by FLT3 ligand (FL)-dependent dimerization and transphosphorylation of tyrosine residues. 3 The FLT3 receptor is either overexpressed in the wild-type form or expressed in a constitutively activated mutant form in many types of acute leukemias. Studies have shown that the overexpression of FLT3 receptor is also frequently associated with constitutively activated autocrine FL expression in many leukemias. 1, 2 Internal tandem duplication (ITD) mutations in the juxtamembrane region have been shown in up to 34% of patients with acute myeloid leukemia (AML), 5% of patients with MDS and 3% of children with acute lymphoblastic leukemia (ALL). 1, 2, 4 In addition, activating missense mutations have been found at D835 or I836 in the activation loop of the kinase region of FLT3 in 8% of AML, 3.1% of MDS and 2.8% of ALL patients.
1,2,5 FLT3 overexpression and/or the occurrence of activating mutations has also been observed in leukemias with chromosomal translocations affecting RUNX1, CBFb, RARa and MLL. 1, 2, 6 The high incidence of FLT3 mutations in AML makes it one of the most frequent genetic alterations in this malignancy.
1,2 A number of studies indicate that patients with activating FLT3 mutations have a worse prognosis than patients expressing wild-type FLT3. 1, 2 Although the full consequences of FLT3 constitutive activation in leukemic cells is not yet clear, it is possible that FLT3 plays a role in promoting proliferation and blocking differentiation and apoptosis that characterizes the leukemic phenotype. Normally, activation of FLT3 by its cognate ligand, FL, leads to receptor autophosphorylation and further signal transduction through direct phosphorylation or association of downstream signaling molecules, including PLC, p85-PI3 K, Vav, Cbl, Shc, Shp2, Ship, Stat 5A and B, Grb2, Gab1 and 2 and the Ras/MAPK pathway. Mutated FLT3 has been found to confer strong constitutive activation of Stat5, Cbl, Vav, Shp2 and Akt. 1, 2, 7, 8 The constitutive activation of these signaling proteins is likely to mediate the observed effects of FLT3/ITDs and D835 mutations.
Injection of FLT3-ITD-transformed Ba/F3 or 32D cells into syngeneic recipient mice causes a leukemia-like syndrome that is not observed by inactivation of the parental cells. 2 In murine bone marrow transplant (BMT) models, retroviral transduction of FLT3/ITD or FLT3/D835Y mutations into primary murine bone marrow cells leads to myeloproliferative disease (MPD) or lymphoid disorder in recipient mice. 9, 10 In a transgenic murine model, expression of FLT3/ITD, driven by the vav-promoter results in non-transplantable MPD or B-or T-lymphoid disorders. 11 Introduction of an additional mutation, such as PML-RARa, AML1-ETO or MLL-related rearrangements triggers the onset of leukemia. [12] [13] [14] The above findings based on murine models support the idea that FLT3 plays a vital role in the pathogenesis of leukemia. Additional cooperative oncogenic signals are required to induce leukemia.
The FLT3 gene encodes a receptor tyrosine kinase that is normally expressed in the CD34 þ fraction of human BM and a small fraction of CD34 À cells (CD14 þ ) destined to become dendritic cells (DCs). 15, 16 FLT3 plays important roles in the survival and proliferation of multipotent hematopoietic stemprogenitor cells (HSPCs), [16] [17] [18] B-cell progenitors, 19 natural killer (NK) cells and DCs. 20, 21 Previous results suggest that early progenitor cells (CFC-GEMM) might be more dependent on the putative signaling function of the FLT3 kinase. 16, 22 The type III tyrosine kinase receptor family, consisting of five membersFFLT3, KIT, FMS, and two genes for PDGFRFis characterized by five immunoglobulin-like folds in the extracellular domain, a single transmembrane domain and an interrupted tyrosine kinase domain in the intracellular region. 23, 24 Tel is a member of the ETS family of transcriptional factors and is reported to be involved in several chromosomal translocations producing fusion proteins such as Tel-PDGFR in CMML, Tel-ABL in AML and Tel-JAK2 in ALL, all of which result in activated tyrosine kinase domains and cause transformation when expressed in hematopoietic cells. 25 Previously, we developed a model of activated FLT3 receptor by fusing the helix-loop-helix (HLH) domain of Tel to the entire cytoplasmic domain of the FLT3 receptor. 25 This fusion mimics the Tel-PDGFR chromosomal translocation found in a subset of CMML patients with t(5,12). 25, 26 Recently, a similar fusion of Tel-FLT3 was observed in a patient with myeloproliferative disorder. 27 The Tel-FLT3 fusion we constructed shares a high degree of structural similarity with the fusion seen in this patient: the intact HLH domain of Tel at the N-terminus fused to the tyrosine kinase domain of FLT3 at the C-terminus. Both of the fusion proteins confer constitutive activation on FLT3 and induce factor-independent growth in transfected Ba/F3 cells. Our previous results also showed that mice injected with Tel-FLT3-transfected Ba/F3 cells developed leukemia. 25 In this report, we generated and analysed transgenic mice expressing the constitutively phosphorylated Tel-FLT3 fusion protein to determine whether activated FLT3 is capable of inducing a leukemic phenotype and whether the mice might have increased expression of certain lymphoid or myeloid cells which might give a proliferative/survival advantage in those cell types. Analysis was also performed to determine if activated FLT3 expression increases the stem/progenitor cell population.
Materials and methods

Generation of transgenic mice
The construction of the Tel-FLT3 fusion was performed by polymerase chain reaction (PCR) as described previously by Tse et al. 25 The cytomegalovirus (CMV)-driven Tel-FLT3 fragment was isolated from the pCIneo plasmid by AlwNI digestion and submitted to the Johns Hopkins Transgenic Core Facility for microinjection into the mouse cross (C57BL/6 Â C3H) pronucleus and subsequent insertion into the uterus of pseudopregnant females. PCR and Southern blotting genotyping was conducted on genomic DNA isolated from tail tips of the resultant mice. Primers used for PCR were from the pCIneo vector [5 0 -CAGCTCTTAAGGCTAGAG-3 0 ] and FLT3 kinase region [5'-CTCATTATCTGAGGAGCC-3']. Genomic DNA was digested with XhoI and subjected to Southern blotting analysis by probing with a 991-bp BstXI/BstXI DNA fragment (Figure 1a) . Inbred mice were obtained by backcrossing with C57BL/6 mice (NCI, Frederick, MD, USA) for seven generations. Mice were housed in a temperature/humidity controlled environment and fed commercial rodent chow and acidified water ad libitum.
Western blotting analysis
Cells from brain, thymus, heart, lung, liver, spleen, BM and testes/ovaries of Tel-FLT3 transgenic and littermate control mice were pelleted and lysed in detergent buffer as described previously. 25 Cell lysates were immunoprecipitated with anti-FLT3 antibody (S-18, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and immunoblotted with anti-phosphotyrosine antibody (4G10, Upstate Biotechnology, Charlottesville, VA, USA) and anti-FLT3 antibody (C-20, Santa Cruz Biotechnology) for the detection of phosphorylation and protein expression, respectively.
Histopathology
Complete necropsies were performed and histopathology examinations were carried out on spleen, liver, thymus, BM and lymph nodes from both the transgenic and non-transgenic littermates. Tissue samples were fixed by immersion in 10% neutral-buffered formalin, embedded in paraffin, and 5-mm tissue sections were stained with hematoxylin and eosin (H&E). Representative images of H&E-stained sections were acquired using a Zeiss Axioskop upright microscope Â 100-400 magnification and a Nikon DMX 1200 digital camera.
Complete peripheral blood cell count
Peripheral blood was collected from mouse retro-occular vessels and subjected to complete blood cell counting (CBC) and white blood cell (WBC) differential using a Hemavet950 Hematology system (Drew Scientific Inc., Oxford, CT, USA). Blood smears were prepared and stained with Wright-Giemsa solution (Sigma-Aldrich, St Louis, MO, USA). and from a wild-type control mouse, and lysates containing 500 mg protein were immunoprecipitated with an anti-FLT3 antibody and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (0.8%). The proteins were then transferred onto a PVDF membrane and immunoblotting performed with 4G10 antibody (anti-phosphotyrosine) (upper panels), followed by stripping and probing with anti-FLT3 antibody (lower panels).
Flow cytometry
Spleens and thymuses were collagenase-treated and the separated lymphoid and adherent fractions were analysed for relevant markers. Cells were rinsed in IFA medium and incubated with antibodies CD14, Mac1, Ly-6G, CD86, CD11c, I-A b , CD4, CD8a, CD3e, CD45R/B220, CD and NK1.1 as described previously. 28 Flow cytometry analysis was performed on a FACSort flow cytometer using CellQuest software (Becton Dickinson, Mountain View, CA, USA).
CFC and CFU-S Assays
In vitro clonogenic assays were performed in quadruplicate in 35-mm petri dishes as described previously. 29 Murine BM or spleen cells were cultured in IMDM containing 1% methylcellulose supplemented with 50 ng/ml SCF, 10 ng/ml interleukin-3 (IL-3), 10 ng/ml IL-6, 10 ng/ml granulocyte macrophage-colony stimulating factor and 3 U/ml EPO (Stemcell Technologies, Vancouver, BC, Canada), with or without the addition of 100 ng/ml FL (ImClone, NY, USA). Colonies were scored 11 days after plating using a Leitz diavert microscope.
CFU-S assays were performed by injecting 1 Â 10 5 cells into the lateral tail vein of irradiated (9 Gy) C57BL/6 mice. Recipient spleens were removed 13 days following injection and fixed in Carnoy's solution (57% ethanol, 30% chloroform and 13% glacial acetic acid) for 16 h at room temperature. Spleens were then rinsed with 70% ethanol and colonies were macroscopically counted.
Homing assay
Total BM cells from transgenic Tel-FLT3 mice or control littermates were labeled with a membrane-bound dye PKH26 (Sigma) as per manufacturer's instructions and injected into the lateral tail vein of control littermate mice. Spleens and BM cells were harvested 2 days post-injection and analysed by FACScan flow cytometer (Becton Dickinson).
BM transplantation assay
BM cells from Tel-FLT3 transgenic mice with MPD were harvested, washed, resuspended in phosphate-buffered saline at a concentration of 5 Â 10 6 cells/ml and injected into the lateral vein of lethally irradiated (10 Gy) C57BL/6 recipient mice at a number of 1 Â 10 6 cells (0.2 ml) per mouse. Recipient mice were monitored daily and complete peripheral blood cell counts were performed every 4 weeks and the mice were observed for more than 200 days.
Results
CMV-Tel-FLT3 transgenic mice express functional protein
Two out of 23 founder mice were identified to carry the CMVTel-FLT3 transgene (referred to as Founders 420 and 421). Southern blotting analysis showed that more than one copy of the construct exists in each founder (data not shown). Western blotting analysis performed on offspring from both founders showed Tel-FLT3 protein expression present in a number of tissues, including spleen, BM, thymus, brain, heart, liver, kidney and lung (Figure 1b, lower panel) . Constitutive phosphorylation of the fusion was seen in all tissues (Figure 1b, upper panel) . No Tel-FLT3 protein expression was seen in negative control littermates.
Tel-FLT3 transgenic mice develop MPD
Because constitutively activated FLT3 mutations are seen in humans with AML, the transgenic mice expressing activated FLT3 were monitored for the development of leukemia. Mice were followed for up to 2.5 years and exhibited no signs of illness, nor succumbed to leukemia despite the long period of observation.
To determine if any mice showed evidence of hematopoietic pathology, transgenic mice of various ages were killed, along with non-transgenic littermates. Transgenic mice from both founder lines frequently developed splenomegaly with splenic weights ranging up to 4.0 g. Splenomegaly was not observed in young mice, but was seen after a minimal lag of 6 months ( Table 1 ). The percentage of mice with splenomegaly increased over time with 15% at 6-18 months and 64% of mice older than 18 months affected. No splenomegaly was observed in the control littermates.
Microscopic examination of the H&E-stained spleen sections from control littermate mice showed a well-defined normal architecture with distinct red and white pulp. In contrast, spleen architecture from the Tel-FLT3 mice was disrupted with marked myeloproliferative changes (Figures 2a and b) . The red pulp of the enlarged spleens generally had large areas of immature myeloid-appearing cells. BM from the Tel-FLT3 transgenic mice showed evidence of hypercellularity, with various degrees of myeloproliferation (Figures 2c and d) . The lymph nodes in some of the Tel-FLT3 mice displayed diffuse areas of hypercellularity, with some of the sinuses containing megakaryocytes and immature myeloid-appearing cells (Figures 2e and f) . Only a few of the Tel-FLT3 mice had appreciable lymphadenopathy. The livers from the Tel-FLT3 transgenic mice with enlarged spleens frequently showed evidence of a hepatic population of erythroid, megakaryocytic and immature myeloid-appearing cells within the parenchyma and sinusoids (Figures 2g and h ). In contrast, livers from the littermate control mice only showed well-organized hepatic architecture, without the myeloidappearing population noted in the transgenic mice.
CBC analysis showed significant increases in the absolute number of monocytes and neutrophils in 18-month-old transgenic mice as compared with their littermate controls, with a mean neutrophil count of 1969/ml (n ¼ 11) in the transgenics as compared with 649/ml (n ¼ 5) (Figure 3a) in the controls and a mean monocyte count of 386/ml (n ¼ 11) as compared with 89/ml in the controls (n ¼ 5) (Figure 3b) . No consistent differences were seen in the counts of total WBC, hemoglobin, hematocrit or platelets between the transgenic mice and their nontransgenic littermate controls (data not shown).
Recently, Vu et al reported that a patient with MPD resulting from a Tel-FLT3 fusion has increased eosinophils. 27 We also observed an increase in eosinophils in the 18-month old transgenic mice (267/ml, n ¼ 11) compared with the wild-type controls (156/ml, n ¼ 5), but this difference was not statistically significant (P ¼ 0.35, Figure 3c) . No difference in the number of basophils was observed between the transgenic and wild-type mice (50/ml and 41/ml respectively, P ¼ 0.80) (Figure 3d ).
Activated FLT3 expression increases the dendritic and NK cell populations
As treatment of mice with FL ligand has been found in vivo to expand natural killer (NK) cells, DCs, and immature B cells. 
Activated FLT3 expression increases the stem cell/ progenitor cell population
Reports from studies with FLT3 knockout mice have shown that targeted CD135 disruption impairs the development of multipotent stem cells, with significant impact on lymphoid precursors. 31 We sought to determine if the expression of Tel-FLT3 results in an increase in early hematopoietic progenitor cells by performing both in vivo CFU-S assays and in vitro colony-forming unit cell assays (CFC).
Both BM and spleens were harvested from 18-month-old mice carrying the transgene and from nontransgenic littermate control mice and CFU assays performed. The frequency of precursors for the granulocyte/monocyte lineage (CFU-GM) in Tel-FLT3 transgenic mice was significantly increased in both the BM and spleen, both with and without FL ligand (179714.2 (P ¼ 0.001) and 146731.4 (P ¼ 0.05) for BM, respectively and 53.5716.9 (P ¼ 0.009) and 6075 (Po0.001) for spleen respectively) Figure  5a and b). The numbers of BFU-E and CFU-GEMM without FL ligand were also significantly increased in the spleen of Tel-FLT3 mice (38.3 þ 3.8 (P ¼ 0.001) and 6.5 þ 2.1 (P ¼ 0.002), respectively) as compared with control (22.374.3 and 0.571, respectively) (Figure 5b) . Similar results were obtained in experiments using cells from either of the founder lines.
We also wanted to determine if the number of more primitive CFU-S progenitors present in the BM of Tel-FLT3 mice was affected by expression of activated FLT3. BM cells from Tel-FLT3 transgenic and littermate control mice were injected via tail vein into lethally irradiated C57BL/6 recipients. The frequency of CFU-S progenitors in the BM were significantly increased in the transgenic mice as compared with the negative littermate control mice (15.173.5, 14.972.4 and 1072.1% for founder lines 420, 421 and littermate controls, respectively) (Figure 5c ). Activated FLT3 could also play a role in the homing of HSPCs and this could account for some of the effects observed in the mice. To answer this question, we used PKH26, a membranebound dye, to follow the fates of hematopoietic stem cells upon transplantation. PKH-positive cells which home to the BM following transplantation are the best long-term engrafting HSC fractions. 32 Therefore, total BM from either the Tel-FLT3 transgenic or littermate control mice was labeled with PKH and injected into the tail veins of lethally irradiated mice. Fortyeight hours later, BM was harvested from the recipients and analysed by FACS for the presence of PKH-labeled cells. No differences were seen in the homing of PKH-labeled BM cells from the two groups (data not shown).
There was no MPD observed in lethally irradiated mice that received 1 Â 10 6 BM cells from MPD mice from either of the two independent founder lines (420 and 421). This indicated that the MPD in the Tel-FLT3 transgenic mice is not transplantable. This finding is consistent with the observations that neither the MPD from FLT3/ITD retroviral infected BM nor from the vav-FLT3/ITD transgenic mice is transplantable.
9,11
Discussion
This study confirms that the expression of an activated FLT3 alone is not sufficient to cause leukemia. This is consistent with findings in leukemia and solid tumors that additional genetic 'hits' are required to fully transform primary cells. The Tel-FLT3 transgenic mice analysed show evidence of MPD in several organs (spleen, BM, lymph nodes, and liver). This MPD phenotype generally developed after a long lag period in the transgenic mice (46 months). This further implies that the expression of activated FLT3 alone may be insufficient to develop MPD and that the lag period is required to develop an additional mutation(s). Tyrosine kinase inhibitors, such as AG1295, AG1296 and CEP-701, can block FLT3-dependent growth and transformation both in vitro and in vivo. 1, 33, 34 It will be interesting to determine whether these drugs can reverse the MPD phenotype in the older Tel-FLT3 transgenic mice.
Other murine models of constitutive FLT3 activation have been previously reported, and differ somewhat from our results. Retroviral infection of mouse BM with an MSCV-based vector expressing FLT3/ITD mutations with subsequent BM transplantation confers a fatal MPD in a large percentage of the transplanted mice by 40-60 days. 9 There are several possible explanations for the differences in the transgenic results reported here and those of the retroviral experiments. First, the retroviral vector used in the transplant study results in a much higher level of expression of activated FLT3 than the CMV promoter used in our study. Thus, the level of expression of activated FLT3 could well affect the lag and aggressiveness of the resultant MPD. Second, the MPD phenotype in the retroviral study resulted from a limited number of integration events, as evidenced by it being oligoclonal and not polyclonal. This implies the integration sites of the retrovirus may also be contributing to the MPD observed by activating additional proto-oncogenes or through inactivation of tumor suppressor genes, thus providing the second 'hit' necessary for the development of the disease. Third, although both FLT3/ITD and Tel-FLT3 fusions result in the constitutive activation of FLT3, it is possible that the two mutations initiate somewhat different signaling processes, therefore leading to different phenotypic consequences. Retroviral transduction of BM cells by the Tel-FLT3 fusion, followed by BMT, will be an important future experiment to help clarify this issue. An MPD phenotype has also been observed in a FLT3/ITD transgenic murine model, in which FLT3 expression was driven by the very active vav promoter.
11 B and T lymphoid disorders also occurred in two of their founder lines. This could be due to the expression of FLT3/ITD in B and T lineages directed by the vav promoter. 35 FACS analysis of the transgenic Tel-FLT3 mice shows a large increase in DCs. This result might have been predicted because FL treatment of mice for 9-10 days results in a dramatic expansion of DCs in the peripheral blood as well as in multiple tissues, 36 including the spleen, lymph node, lungs, liver, Peyer patches and thymus. 37 DCs expanded by FL are important in processing and presenting antigens to naïve T lymphocytes, particularly memory CD4 þ and CD8 þ T cells. 30, 38, 39 Additional evidence for the importance of FL comes from FL-null mice in which there is a reduction in DC numbers in the spleen, lymph node and thymus. 30 We also found NK cells to be elevated in the BM of the transgenics. This is consistent with the results in the FL-null mice which have a deficiency of NK cells. 30 Studies have also shown that FL stimulation may have an anti-leukemic effect, and that the effect requires NK cells. 40 In addition, a number of studies have appeared on the use of FL for decreasing growth of colon tumor and melanomas, 41, 42 and for enhancing the immunogenicity of infectious disease vaccines such as HIV-1, polyomavirus and herpes simplex virus 1. 43, 44 Tel-FLT3 mice could provide a valuable tool for in vivo expanded DCs and NK cells for antitumor studies.
We found a significant increase in the number of CFCs from the BM and spleens of the transgenic mice, which indicates that the activated FLT3 receptor is involved in the expansion of HSPCs. Previous results have shown that FL ligand acts synergistically with other factors such as SCF, IL-3, IL-6 and G-CSF to support expansion of hematopoietic progenitors in vitro. 17, 20, 30 This is consistent with the findings in both the homozygous FLT3 receptor knockout and FL knockout mice, which were found to have reduced myeloid and lymphoid progenitor population. 30, 31 There is evidence that the FLT3-expressing fraction of HSPCs is characterized by short-term engrafting or low-quality stem cells. 22 FL has the biggest effect on primitive hematopoietic progenitor cells. 8 Studies have demonstrated that leukemias arise from a very small population of cells, termed leukemia stem cells (LSCs), that gain indefinite proliferation potential through accumulating mutations in normal HSCs or committed progenitor cells. 45 Many signaling pathways associated with LSCs are shared in HSC development. The contributions of FLT3-activating mutations in the leukemic transformation of normal HSPCs have not yet been fully elucidated. Recent studies demonstrate that FLT3/ITD mutations usually do occur in the LSCs of AML. 29 In the CFU-S in vivo assays, we observed increases in the number of colonies from the BM of transgenics as compared to their littermate controls. This indicates that activated FLT3 also stimulates myeloid progenitor cells at a relatively primitive stage. Additional long-term engrafting experiments will be required to determine the effects on more primitive cells and possibly leukemia.
As discussed above, an MPD phenotype has now been demonstrated in several murine models, with constitutively activated FLT3 expression. Despite the frequent occurrence of abnormal FLT3 activation in leukemias, so far no phenotype of leukemia has been reported in murine models. However, leukemia is the consequence when additional mutations, such as PML-RARa, AML1-ETO, or MLL-rearranged fusion genes, are combined with activated FLT3. [12] [13] [14] These observations support the idea that FLT3 plays an important role in leukemogenesis, but alone is insufficient to induce leukemia. The ' second-hit' theory indicates that breeding activated FLT3 transgenic mice to mice that already have other 'hits', will often result in transformation to leukemia.
